资讯

Ophthalmology Times17 小时
Harrow enters into agreement with Samsung Bioepis for commercial rights to its ...
Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...
Ophthalmology Times23 小时
AAVantgarde Bio receives IND clearance for AAVB-039
AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.